Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands, including PSMA-targeted PNT2001 program.
Lead Product(s): PNT2001
Therapeutic Area: Oncology Product Name: PNT2001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Point Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 04, 2023